The Chop Finally Turned into a New Record High
Recap - The range that had dominated trading in the S&P 500 for all of 2015 (which we wrote about last weekend) finally came to an end this Friday (the … Continue Reading
Read NowzFree
Kyle Bass Plans to Crush Drug Patents – and Pharma Stocks
Insights - In healthcare and pharmaceutical news this week, famed predictor of the subprime mortgage crisis and hedge fund manager Kyle Bass has taken aim at the … Continue Reading
Read Now
Another Gene Therapy Developer Partners Up, This Time with Genzyme
Insights - Genzyme (of Sanofi [SNY]) announced on Wednesday a collaboration with the private gene therapy company Voyager Therapeutics.
Read Now
“Chop” is Still the Name of the Game in the Markets
Pfizer to Strengthen Established Products Business with Hospira Acquisition
Insights - Pfizer (PFE) announced plans to buy injectable generics & biosimialar developer Hospira (HSP) at $90/share, for an enterprise value of $17 billion. Hospira closed Wednesday at $64.80.
Read Now
For the First Time, the FDA Takes Back a Breakthrough Therapy Designation
Insights - Merck (MRK) revealed on Wednesday that the U.S. FDA has rescinded a Breakthrough Therapy Designation for its investigational Hepatitis C treatment.
Read Now
